Mereo BioPharma Group (MREO) Operating Leases: 2020-2024
Historic Operating Leases for Mereo BioPharma Group (MREO) over the last 1 years, with Dec 2024 value amounting to $187,000.
- Mereo BioPharma Group's Operating Leases fell 79.36% to $187,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $187,000, marking a year-over-year decrease of 79.36%. This contributed to the annual value of $187,000 for FY2024, which is 79.36% down from last year.
- Per Mereo BioPharma Group's latest filing, its Operating Leases stood at $187,000 for Q4 2024, which was down 52.54% from $394,000 recorded in Q3 2024.
- Mereo BioPharma Group's Operating Leases' 5-year high stood at $2.4 million during Q4 2021, with a 5-year trough of -$1.8 million in Q2 2020.
- In the last 3 years, Mereo BioPharma Group's Operating Leases had a median value of $552,000 in 2024 and averaged $620,944.
- As far as peak fluctuations go, Mereo BioPharma Group's Operating Leases surged by 77.66% in 2021, and later plummeted by 79.36% in 2024.
- Over the past 5 years, Mereo BioPharma Group's Operating Leases (Quarterly) stood at $1.5 million in 2020, then skyrocketed by 54.63% to $2.4 million in 2021, then plummeted by 37.45% to $1.5 million in 2022, then crashed by 38.74% to $906,000 in 2023, then tumbled by 79.36% to $187,000 in 2024.
- Its Operating Leases was $187,000 in Q4 2024, compared to $394,000 in Q3 2024 and $552,000 in Q2 2024.